Thromboelastography in pre-surgery monitoring in Hemophilia A with high inhibitor titer: case report and literature review

Authors:
  • GGGeorgiana Gheorghe
    Georgiana Gheorghe
  • ECElisabeta Chiriac
    Elisabeta Chiriac
  • CCClaudia Ciobanu
    Claudia Ciobanu
  • HOHoria Orban
    Horia Orban
  • ANAnd
    And
Open Access
Publisher website
Google Scholar
Abstract
The development of factor VIII inhibitors (allo-antibodies) continues to be a major complication in the management of severe forms of hemophilia A, especially as far as treatment and treatment response monitoring is concerned. The need to implement a reliable laboratory assay is all the more obvious if major surgery occurs, when conventional tests (activated partial thromboplastin time APTT, prothrombin time PT, factor VIII level) are of no avail and there is a very fragile balance between bleeding and thrombosis. We report the case of a 32 year-old patient diagnosed with severe Hemophilia A, referred to the Comprehensive Center for the Diagnosis and Treatment of Hemophilia of the Fundeni Clinical Institute for a multidisciplinary assessment in view of a total left hip arthroplasty due to aseptic necrosis of the femoral neck. Workup showed a high inhibitor titer (>200 BU). Taking into consideration the interindividual variability of the response to bypassing agents, as well as the bleeding risk associated with a major orthopedic surgery, we used thromboelastography (TEG) to assess the patient’s response to aPCC (activated prothrombin complex concentrate) and rFVIIa (activated recombinant factor VII). The findings helped select the optimal replacement scheme to ensure perioperative hemostasis.

This publication has 24 references indexed in Scilit: